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Despite genetic evidence implicating MBD5 as the only overlapping gene between various 2q23.1 microdeletions, the function of MBD5 and its causality to 2q23.1 microdeletion syndrome, a disorder characterized by developmental delay and autistic features, has yet to be determined. In this issue of EMBO Molecular Medicine, Camarena et al generate an Mbd5 genetrap mouse model and show for the first time that mice with reduced MBD5 expression develop behavioral abnormalities with neuronal function deficits, mimicking symptoms in 2q23.1 microdeletion syndrome, thus supporting a causal role for MBD5 haploinsufficiency in the disorder.
See also: Camarena V et al (August 2014) C hromosomal aberrations have been implicated in numerous developmental disorders. Among those is the 2q23.1 region, in which deletions and duplications lead to neurological disorders characterized by autism features and developmental delay (Mullegama et al, 2014) . Patients with microdeletions in 2q23.1 typically present with intellectual disability, motor dysfunction, seizures, microcephaly, and craniofacial abnormalities (van Bon et al, 2010) . The size of these deletions is highly variable and includes several previously identified disease-risk genes. Alignment of the deletion regions revealed a single overlapping locus spanning the methyl-CpG-binding domain 5 (MBD5) gene. This finding, accompanied by decreased MBD5 mRNA expression in patient samples, suggested that MBD5 haploinsufficiency is responsible for the observed disease manifestations (Talkowski et al, 2011; Williams et al, 2010) . However, a causal role for MBD5 in 2q23.1 microdeletion syndrome has yet to be established.
MBD5 is a member of the methyl-CpGbinding domain (MBD) family of proteins, which includes MBDs 1 to 6, MeCP2, SETDB1, SETDB2, BAZ2A, and BAZ2B (Klose & Bird, 2006) . These proteins share an MBD domain, a conserved region of about 70 amino acids, and are believed to recognize DNA methylation and mediate chromatin modification and gene regulation, except MBD3, MBD5, and MBD6 that show weak binding to methylated DNA (Laget et al, 2010) . MBD5, however, also contains a PWWP domain that recognizes histone methylation (Wu et al, 2011) . Previous studies demonstrated that loss of the proteins that serve to read and interpret DNA methylation has deleterious effects and been linked to several neurodevelopmental disorders. Mutations in MBD1, MBDs 3 to 6, SETDB1, and SETDB2 have been genetically implicated in autism (https://gene.sfari.org), and mutations in MECP2 are responsible for Rett syndrome, a neurodevelopmental disorder that shares features with autism (Chahrour & Zoghbi, 2007) . Notably, mutations in MBD5 have been estimated to contribute to up to 1% of all autism spectrum disorder cases (Talkowski et al, 2011) . However, the function of MBD5 and its mechanism of action remain virtually unknown.
In this issue, Camarena and colleagues set out to test the functional significance of MBD5 and its relationship to 2q23.1 microdeletion syndrome (Camarena et al, 2014) . The expression pattern of murine Mbd5 was found to be similar to that of human MBD5, and both are expressed in multiple isoforms in the brain. To examine the phenotypic consequences of Mbd5 deficiency, the authors generated an Mbd5 gene-trap mouse (Mbd5 GT ), in which a genetrap cassette was inserted into intron 2 of Mbd5 in order to disrupt protein production.
This inclusion also allowed them to use X-gal as a proxy to examine MBD5 expression at a cellular level. Interestingly, they observed high X-gal expression in early embryonic stages that was primarily limited to neurons. Unexpectedly, the gene-trap cassette did not completely disrupt the production of full- neurons were reduced compared to neurons from wildtype mice, suggesting a role for MBD5 in proper neuronal development. To ascertain how MBD5 might be functioning, the authors took a reporter approach and performed a luciferase assay, finding that MBD5 could act as a transcriptional activator. Consistent with this result, immunocytochemistry experiments showed that MBD5 localizes to non-heterochromatin regions of the nucleus, in contrast to heterochromatinassociated MeCP2, an MBD family member known to mediate gene silencing. Although their approach is limited in reflecting the endogenous function of MBD5, these findings suggest that MBD5 may act differently from other MBDs in regulating downstream gene activity.
Taken together, the authors of this paper have developed a valuable genetic tool with the potential to dissect the pathogenic mechanisms of 2q23.1 microdeletion syndrome. Their mouse model is also useful in studying the function of MBD5, of which very little is known despite its clinical relevance. How MBD5 may activate gene transcription to influence neuronal maturation and contribute to the behavioral phenotypes observed in Mbd5 +/GT mice has yet to be determined, although their model is one significant step in advancing our knowledge of this devastating disorder. Interestingly, both duplications and deletions in MBD5 have been linked to neurodevelopmental abnormalities (Mullegama et al, 2014) . Likewise, deletions and duplications of MECP2 give rise to the neurodevelopmental disorders, Rett Syndrome and MECP2 Duplication Syndrome (Chahrour & Zoghbi, 2007) , suggesting that proper dosage of MBD genes is critical for normal neurological development. This observed dosage effect would determine how future therapies are developed, as attaining a precise amount is of critical importance. In addition to the brain, MBD5 is also expressed in peripheral tissues, particularly in the heart and kidney. The generation of conditional knockouts is needed to further delineate the function of MBD5 in these specific tissues and may circumvent the perinatal lethality seen in homozygous-null animals. Understanding the downstream effect of MBD5 haploinsufficiency is another significant challenge. Given that MBD5 is highly expressed in neurons, the identification of its downstream gene targets is a considerably difficult task due to the complex cellular heterogeneity of the brain. Thus, future work is needed to establish how MBD5 functions in each neuronal type and to determine which are most vulnerable to its loss or overexpression. These studies may shed light not only on the cellular origins of 2q23.1 microdeletion syndrome but also other related neurodevelopmental disorders and may provide much needed avenues of therapeutic development.
